易瑞生物 reported revenue of ¥0.13B for the period ended 2026-06-30, +17.5% year on year. Net income was ¥-0.02B, a -15.1% net margin on a 59.0% gross margin. The largest revenue line is 检测试剂 at 70% of the total. Free cash flow for the period was ¥0.00B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.13B | +17.5% |
| Gross profit | ¥0.08B | — |
| Operating income | ¥-0.02B | — |
| Net income | ¥-0.02B | -1126.4% |
| Gross margin | 59.0% | Net margin -15.1% |
| Revenue Q/Q | +22.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| 检测试剂 | ¥0.09B | 69.7% |
| 其他 | ¥0.01B | 11.5% |
| 检测服务 | ¥0.01B | 9.8% |
| 检测仪器 | ¥0.01B | 8.9% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.05B | 41.0% |
| R&D | ¥0.02B | 17.1% |
| SG&A | ¥0.06B | 44.5% |
| Tax & other | ¥-0.00B | -3.5% |
| Item | Amount |
|---|---|
| Total assets | ¥1.48B |
| Total liabilities | ¥0.60B |
| Shareholders' equity | ¥0.88B |
| Equity / assets | 59.5% |
| Operating cash flow | ¥0.01B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.00B |
| Cash conversion (OCF / net income) | 30% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
春晖智控 ・ 曼卡龙 ・ 恒而达 ・ 德必集团 ・ 冠中生态 ・ 奥雅股份 ・ 德固特 ・ 博硕科技 ・ 恒辉安防 ・ 震裕科技 ・ 嘉亨家化 ・ 英力股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies